JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Aandelen Lijst・Aclaris Therapeutics Inc
Search

Aclaris Therapeutics Inc

Gesloten

4.41 1.85

Strong Buy

Prijsupdate 1 mei 2026, 19:58 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.33

Max

4.41

Belangrijke statistieken

By Trading Economics

Inkomsten

-5.2M

-20M

Verkoop

-2M

1.3M

Winstmarge

-1,528.571

Werknemers

69

EBITDA

-5.3M

-20M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+156.92% upside

Dividenden

By Dow Jones

Volgende Winsten

7 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

264M

616M

Vorige openingsprijs

2.56

Vorige sluitingsprijs

4.41

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

1.28 / 1.33 Steun & Weerstand

Aclaris Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 mei 2026, 22:17 UTC

Winsten

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Lezen

4 mei 2026, 23:47 UTC

Winsten

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Lezen

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Lezen

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Lezen

4 mei 2026, 23:40 UTC

Marktinformatie

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Lezen

4 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Lezen

4 mei 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Lezen

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Lezen

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Lezen

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Lezen

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Lezen

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Shareholders to Own About 51% of Combined Company

DJ

Lezen

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Lezen

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Deal Unanimously Recommended by Vault Board

DJ

Lezen

4 mei 2026, 22:39 UTC

Acquisities, Fusies, Overnames

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Lezen

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Lezen

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Lezen

4 mei 2026, 22:37 UTC

Winsten
Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Lezen

4 mei 2026, 22:26 UTC

Winsten
Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Lezen

4 mei 2026, 22:02 UTC

Winsten

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Lezen

4 mei 2026, 22:00 UTC

Marktinformatie

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Lezen

4 mei 2026, 21:52 UTC

Winsten

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Lezen

4 mei 2026, 21:50 UTC

Winsten

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Lezen

4 mei 2026, 21:50 UTC

Winsten

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Lezen

4 mei 2026, 21:49 UTC

Winsten

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Lezen

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Lezen

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Lezen

4 mei 2026, 21:43 UTC

Winsten

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Lezen

4 mei 2026, 21:41 UTC

Winsten

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Lezen

4 mei 2026, 21:40 UTC

Winsten

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Lezen

Peer Vergelijking

Prijswijziging

Aclaris Therapeutics Inc Prognose

Koersdoel

By TipRanks

156.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 11.33 USD  156.92%

Hoogste 16 USD

Laagste 10 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Aclaris Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Aclaris Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.28 / 1.33Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Neutral Evidence

The bullish and bearish events are balanced.

Lange Termijn

Bearish Evidence

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Andere aandelen uit de sector

JNJ

Johnson and Johnson

225.57

↑ +0.63%

UNH

UnitedHealth Group Inc

363.82

↓-1.87%

TMO

Thermo Fisher Scientific Inc

466.62

↑ +0.92%

ISRG

Intuitive Surgical Inc

451.55

↓-0.21%

ABT

Abbott Laboratories

87.15

↓-0.47%
help-icon Live chat